AR125231A2 - HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS - Google Patents

HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Info

Publication number
AR125231A2
AR125231A2 ARP220100736A ARP220100736A AR125231A2 AR 125231 A2 AR125231 A2 AR 125231A2 AR P220100736 A ARP220100736 A AR P220100736A AR P220100736 A ARP220100736 A AR P220100736A AR 125231 A2 AR125231 A2 AR 125231A2
Authority
AR
Argentina
Prior art keywords
infection
monoclonal antibodies
tetanus
immunotherapies
tetani
Prior art date
Application number
ARP220100736A
Other languages
Spanish (es)
Inventor
Eduardo Aliprandini
Filho Jorge Elias Kalil
Ana Maria Moro
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of AR125231A2 publication Critical patent/AR125231A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos monoclonales humanos anti-toxina de tétano contra una infección por C. tetani, que se obtienen mediante técnicas de ingeniería genética utilizando como base la información de secuencias genéticas obtenida a partir de linfocitos B de sangre periférica de individuos inmunizados con el toxoide del tétano. La información genética se inserta en vectores que se utilizarán para transfectar células de mamífero con el objeto de generar linajes celulares productores de los anticuerpos monoclonales anti-toxina de tétano. En otro aspecto, la presente invención se refiere a composiciones inmunológicas que contienen dicho anticuerpo monoclonal, así como a sus usos en el tratamiento y/o en inmunoterapias de una infección por tétano.Human anti-tetanus toxin monoclonal antibodies against a C. tetani infection, which are obtained by genetic engineering techniques using as a basis genetic sequence information obtained from peripheral blood B lymphocytes of individuals immunized with tetanus toxoid. The genetic information is inserted into vectors that will be used to transfect mammalian cells in order to generate cell lines that produce anti-tetanus toxin monoclonal antibodies. In another aspect, the present invention relates to immunological compositions containing said monoclonal antibody, as well as their uses in the treatment and/or in immunotherapies of a tetanus infection.

ARP220100736A 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS AR125231A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016017782-0A BR102016017782A2 (en) 2016-07-29 2016-07-29 NUTRIENTING ANTITETANIC HUMAN MONOCLONAL ANTIBODIES FOR C.TETANI INFECTION, METHOD FOR OBTAINING MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPY FOR TETANIC BACILE INFECTION

Publications (1)

Publication Number Publication Date
AR125231A2 true AR125231A2 (en) 2023-06-28

Family

ID=59955306

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP170102180A AR109221A1 (en) 2016-07-29 2017-07-31 HUMAN ANTITETHANE MONOCLONAL ANTIBODIES THAT NEUTRALIZE AN INFECTION BY C. TETANI, METHOD FOR OBTAINING THE MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES OF ACCIDENTAL INJURIES SUSCEPTIBLE TO AN INFECTION BY A BATH TANK
ARP220100736A AR125231A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS
ARP220100737A AR125232A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170102180A AR109221A1 (en) 2016-07-29 2017-07-31 HUMAN ANTITETHANE MONOCLONAL ANTIBODIES THAT NEUTRALIZE AN INFECTION BY C. TETANI, METHOD FOR OBTAINING THE MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES OF ACCIDENTAL INJURIES SUSCEPTIBLE TO AN INFECTION BY A BATH TANK

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220100737A AR125232A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Country Status (4)

Country Link
AR (3) AR109221A1 (en)
BR (1) BR102016017782A2 (en)
PH (1) PH12019500431A1 (en)
WO (1) WO2018018123A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845609B (en) * 2019-11-26 2021-06-15 武汉生物制品研究所有限责任公司 Detection antibody pair aiming at tetanus toxoid and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (en) * 1988-08-19 1997-07-02 森永製菓株式会社 Anti-tetanus toxin human monoclonal antibody, neutralizing agent for tetanus toxin using the same, and hybridoma producing human monoclonal antibody
DK0562132T3 (en) * 1992-03-23 1999-03-22 Schweiz Serum & Impfinst Monoclonal antibodies to tetanus toxin and pharmaceutical preparations containing them
JPH1014570A (en) 1996-07-05 1998-01-20 Morihiro Matsuda Antibody dna
CN102453091B (en) 2010-10-20 2013-09-25 上海生物制品研究所有限责任公司 Tetanus toxoid monoclonal antibody and preparation method and application thereof
CN105153305B (en) 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 A kind of full humanized anti-spasmotoxin monoclone antibody and its derivative preparation method and application

Also Published As

Publication number Publication date
PH12019500431A1 (en) 2019-10-28
WO2018018123A3 (en) 2018-03-22
AR125232A2 (en) 2023-06-28
AR109221A1 (en) 2018-11-07
WO2018018123A2 (en) 2018-02-01
BR102016017782A2 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
MY189819A (en) Genetically modified cells and uses thereof
CL2018001971A1 (en) Ror1 antibody compositions and related methods
CL2019000067A1 (en) New antibodies that specifically bind to Zika virus epitopes and uses thereof.
AR110645A1 (en) ANTI-HLA-G ANTIBODIES AND USE OF THE SAME
SV2018005678A (en) ANTIBODY THAT NEUTRALIZES THE HUMAN SYNTHETIC RESPIRATORY VIRUS
BR112018008442A2 (en) chimeric receptors containing traf inducer domains and related compositions and methods
BR112017019140A2 (en) cancer treatment methods using activated t cells
CO2022017670A2 (en) Antibodies against sars-cov-2
BR112016020287A2 (en) virus resistant cells and their uses
PE20170264A1 (en) MONOCLONAL ANTIBODIES AGAINST EPITO HER2 AND THEIR METHODS OF USE
EA201590184A1 (en) VACCINE ON THE BASIS OF MYCOBACTERIAL ANTIGENS
CO7160026A2 (en) Mycoplasma hyopneumoniae vaccine
BR112014026740A8 (en) antibody, composition, method of providing an antibody with enhanced adcc, and, use of an antibody
CR20180503A (en) COMPOSITIONS AND METHODS FOR PROGRAMMING THERAPEUTIC CELLS USING DIRECTED NUCLEIC ACID NANOPPORTERS
BR112015009070A2 (en) fusion protein or antigen cocktail; use of a fusion protein or cocktail of antigens; vaccine; and method for immunizing an animal, including a human, against tuberculosis caused by virulent microbacteria
AR090668A1 (en) ANTI-ADAMTS-5 ANTIBODY, DERIVATIVES AND USES OF THE SAME
PH12017500983A1 (en) Method for creating light and temperature sensitive sterile line, and application of method in plant breeding
CU20210041A7 (en) IMMUNOGENIC PEPTIDES WITH OXIDOREDUCTASE MOTIFS
MX2022003664A (en) Hiv vaccines comprising one or more population episensus antigens.
EA201790558A1 (en) COMPOSITION WITH REDUCED IMMUNOGENICITY
ECSP19008417A (en) ANTIBODIES WITH LOW IMMUNOGENICITY AND USES OF THEM
AR125231A2 (en) HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS
CY1123467T1 (en) THERAPEUTIC VACCINE FOR THE TREATMENT OF CHILDREN'S TYPE 1 DIABETES, APPLICATION OF FLOW CYTOMETRY CELL SEPARATION AND TREG CELL PROPAGATION METHOD FOR THE PRODUCTION OF THERAPEUTIC VACCINE FOR THE TREATMENT OF DIABETES T UNDER 1
MX2020004063A (en) Systems and methods to produce b cells genetically modified to express selected antibodies.
CO2023006684A2 (en) Antibodies against sars-cov-2 and their uses